tiprankstipranks
Bastide le Confort Medical SA (FR:BLC)
:BLC

Bastide le Confort Medical (BLC) AI Stock Analysis

9 Followers

Top Page

FR:BLC

Bastide le Confort Medical

(BLC)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 5.2)
Rating:49Neutral
Price Target:
€22.00
▼(-7.76% Downside)
Action:ReiteratedDate:12/11/25
The overall stock score is primarily impacted by financial performance challenges, including high leverage and declining revenue growth. Technical analysis indicates bearish momentum, and the stock appears overvalued based on its P/E ratio. These factors collectively result in a lower score.
Positive Factors
Operational margins
High gross and EBITDA margins indicate efficient procurement and operational processes that create durable cash generation capacity. Sustained margin structure provides a buffer against revenue volatility, funds for reinvestment in services and devices, and supports long-term service profitability.
Negative Factors
High financial leverage
Very high leverage raises interest and refinancing risk and constrains strategic flexibility. In a capital-intensive home-health model this amplifies downside if revenues decline, increases covenant vulnerability, and limits ability to fund growth without deleveraging.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational margins
High gross and EBITDA margins indicate efficient procurement and operational processes that create durable cash generation capacity. Sustained margin structure provides a buffer against revenue volatility, funds for reinvestment in services and devices, and supports long-term service profitability.
Read all positive factors

Bastide le Confort Medical (BLC) vs. iShares MSCI France ETF (EWQ)

Bastide le Confort Medical Business Overview & Revenue Model

Company Description
Bastide Le Confort Médical SA engages in the sale and rental of medical equipment in France. The company offers comfort and health products, such as lift chairs, bathroom and well-being products, pillows and cushions, seats, phones keys, measuring...
How the Company Makes Money
Bastide le Confort Medical generates revenue through multiple key streams, including the sale of medical equipment and supplies, as well as home healthcare services. The company earns significant income from direct sales to consumers and healthcar...

Bastide le Confort Medical Financial Statement Overview

Summary
Bastide le Confort Medical exhibits strengths in operational efficiency and cash flow management, with solid gross and EBITDA margins and strong free cash flow growth. However, challenges include declining revenue growth, low net profit margins, and high financial leverage.
Income Statement
65
Positive
Balance Sheet
50
Neutral
Cash Flow
70
Positive
BreakdownTTMSep 2025Sep 2024Jun 2023Sep 2022Jun 2021
Income Statement
Total Revenue476.02M491.18M529.75M508.03M468.30M444.07M
Gross Profit49.09M333.00M354.44M333.73M306.80M280.26M
EBITDA98.75M102.03M107.20M98.15M89.83M88.30M
Net Income29.45M528.00K-900.00K12.05M13.68M13.45M
Balance Sheet
Total Assets580.52M661.03M647.07M657.08M632.55M569.11M
Cash, Cash Equivalents and Short-Term Investments25.47M25.49M23.62M36.71M22.13M33.74M
Total Debt324.13M411.16M408.65M427.39M419.23M357.62M
Total Liabilities478.08M589.73M566.34M568.99M545.89M484.05M
Stockholders Equity102.75M72.13M79.77M87.65M84.56M81.31M
Cash Flow
Free Cash Flow29.93M41.74M10.64M36.65M-6.51M19.62M
Operating Cash Flow78.98M101.82M66.04M90.28M46.76M66.13M
Investing Cash Flow27.86M-56.44M-43.65M-76.27M-104.74M-73.45M
Financing Cash Flow-102.88M-4.33M-35.55M-7.89M29.43M1.34M

Bastide le Confort Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price23.85
Price Trends
50DMA
23.97
Positive
100DMA
24.47
Negative
200DMA
25.84
Negative
Market Momentum
MACD
-0.23
Positive
RSI
50.84
Neutral
STOCH
60.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Positive. The current price of 23.85 is above the 20-day moving average (MA) of 23.82, below the 50-day MA of 23.97, and below the 200-day MA of 25.84, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 50.84 is Neutral, neither overbought nor oversold. The STOCH value of 60.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:BLC.

Bastide le Confort Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
€104.35B26.2813.87%2.06%1.46%12.62%
69
Neutral
€490.52M8.565.18%3.95%4.80%-18.25%
68
Neutral
€11.06B32.739.69%0.82%8.28%-8.08%
60
Neutral
€172.80M18.44-5.44%3.79%-797.10%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
49
Neutral
€175.51M1.503.97%-7.28%
43
Neutral
€75.75M-2.58-16.98%-7.84%71.75%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:BLC
Bastide le Confort Medical
24.00
-0.30
-1.23%
FR:AI
Air Liquide
180.52
22.76
14.43%
FR:BIM
bioMerieux
93.65
-15.64
-14.31%
FR:BOI
Boiron SA
28.00
5.05
21.99%
FR:ALCGM
Cegedim
12.60
2.10
20.00%
FR:VTR
Vitura SA
4.44
-3.21
-41.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 11, 2025